1fw 1641

S/N 10/527,510

PATENT
Confirmation No. 9967

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Le et al.	Docket:	16800-48860
Serial No.:	10/527,510	Examiner:	Unassigned
Filing Date:	March 31, 2006	Group Art Unit:	1641
Title:	Methods of Assessing Endothelial Dysfunction Using Acute Transient Responses Following Fat Administration		

CERTIFICATE UNDER 37 CFR 1.8:
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 1, 2007.

By:_____
Name: Tim Tingkang Xia

TRANSMITTAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet (1 page)
- ☒ Supplemental Information Disclosure Statement (37 C.F.R. § 1.97(b)) (2 pages)
- ☒ Form PTO-1449 (2 pages)
- ☒ Copies of Seventeen (17) Non-Patent References
- ☒ Return Postcard

MORRIS, MANNING & MARTIN, LLP
1600 Atlanta Financial Center
3343 Peachtree Road NE
Atlanta, Georgia 30326
404.495.3678
Customer No. 24728

By: _____
Name: Tim Tingkang Xia
Reg. No.: 45,242
TX

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Le et al.	Docket:	16800-48860
Serial No.:	10/527,510	Examiner:	Unassigned
Filing Date:	March 31, 2006	Group Art Unit:	1641
Title:	Methods of Assessing Endothelial Dysfunction Using Acute Transient Responses Following Fat Administration		

CERTIFICATE UNDER 37 CFR 1.8:
The undersigned hereby certifies that this Transmittal Letter and the papers, as described herein, are being deposited via First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on August 1, 2007.

By: _____
Tim Tingkang Xia

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Customer No. 24728

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each non-U.S. patent document or other information listed on the enclosed Form 1449 is provided herewith, if applicable.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Respectfully submitted,

MORRIS, MANNING & MARTIN, LLP

August 1, 2007

Tim Tingkang Xia
Attorney for the Applicants on the Record
Reg. No.: 45,242

Morris, Manning & Martin, LLP
3343 Peachtree Road, N.E.
Atlanta, Georgia 30326-1044
Telephone: 404.233.7000
Customer No. 24728

FORM 1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: **16800-48860**	Serial Number: **10/527,510**
	Applicant: **Le et al.**	Confirmation No.: **9967**
	Filing Date: **March 31, 2006**	Group Art Unit: **1641**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	B1	Avogaro P, Bittolo B, Cazzolato G. Presence of a modified LDL in humans. Arteriosclerosis. 1988; 8:79-87.
	B2	Esterbauer H, gebicki J, Puhl H, and Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radical Biol Med. 1992; 13:341-390.
	B3	Gradek, W. et al. Polyunsaturated fatty acids acutely suppress antibodies to malondialdehyde-modified lipoproteins in patients with vanscular disease. The American Journal of Cardiology Vol. 93. 2004; ppgs. 881-885.
	B4	Holvoet P, Perez G, Zhao Z, et al. Malondialdehyde-modified LDL in patients with atherosclerotic disease. J Clin Invest. 1995; 95:261 1-2619.
	B5	Le NA, Li X, Kyung S, Brown WV. Evidence for the vivo generation of oxidatively modified epitopes in patients with atherosclerotic endothelium. Metabolism: Clinical & Experimental. 200; 49(10):1271-7.
	B6	Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Medge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary articles. NEJM. 1986; 315:1046-105.
	B7	Nable EG, Selwyn AP, Ganz P. Large coronary arteries in humans are responsive to changing blood flow: and endothelium-dependent mechanism that fails in patients with atherosclersis. J AM Call Cardiol. 1994; 16:349-356.
	B8	Pentilainen MO, R Oksjoki, K Oorni and PT Kovanen (2002) Lipoprrptein lipase in the arterial wall: Linking LDL to the arterial extracellular matrix and much more. ATVB 22:211-217.
	B9	Ross R (1999) Mechanisms of Disease: Atherosclerosis-an inflammatory disease. NEJM 340: 115-149.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449 INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: **16800-48860**	Serial Number: **10/527,510**
	Applicant: **Le et al.**	Confirmation No.: **9967**
	Filing Date: **March 31, 2006**	Group Art Unit: **1641**

	B10	Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients woth coronary artery disease. NEJM. 1995; 332(8):481-7
	B11	Vogel RA (1997) Coronary risk factors, endothelial function and atherosclerosis: a review. Clin Cardiol 20: 426-432.
	B12	Wilkinson I, Qasem A, McEniery C, Webb D, Avolio A, Cockcroft J. Nitric Oxide Regulates Local Arterial Distensibility in Vivo. Circulation 2002; 105:213-217.
	B13	Wilson, Peter WF, D'Agostino, R, Levy, D, Belanger, A., Silbershatz, H, Kannel, W. Prediction of Coronary Heart Disease Using Risk Factor Categories. Circulation 1998; 97 918):1837-1847.
	B14	Yla-Herttuala S, Palinski W, Butler S, et al. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arthioscler Thromb. 1994; 14:32-40.
	B15	Yla-Herttuala S, Palinski W, Rosenfeld M, et al. Evidence for the presence of oxidatively modified LDL in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989; 84:1086-1095.
	B16	Zilversmit DB (1973) A proposal linking atherogenesis to the interaction of endothelial lipase with TG-rich lipoproteins. Circ res 33: 633-638.
	B17	Zilvermit DB (1979) Atherogenesis: a postprandial phenomenon. Circulation 60: 473-485.

Customer No. 24728

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.